Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by Targeted codon deoptimization of virulence genes

mBio

Volumn 5, Issue 5, 2014, Pages

  Meng, Jia ^a,b   Lee, Sujin ^a,b   Hotard, Anne L ^a,b   Moore, Martin L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUTRALIZING ANTIBODY; STAT2 PROTEIN; CODON; LIVE VACCINE; VIRAL PROTEIN; VIRULENCE FACTOR; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CODON USAGE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; NS1 GENE; NS2 GENE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN DEGRADATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRAL GENETICS; VIRUS ATTENUATION; VIRUS GENE; VIRUS LOAD; VIRUS STRAIN; VIRUS VIRULENCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; CHLOROCEBUS AETHIOPS; CODON; GENE EXPRESSION REGULATION; GENETICS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; METABOLISM; VERO CELL LINE; VIROLOGY;

RESPIRATORY SYNCYTIAL VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; CODON; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MICE; MICE, INBRED BALB C; NF-KAPPA B; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, ATTENUATED; VERO CELLS; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS; VIRULENCE FACTORS;

EID: 84908434444     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01704-14     Document Type: Article

References (51)

1. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. 2012. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr. Infect. Dis. J. 31:5-9. http://dx.doi.org/10.1097/INF.0b013e31822e68e6.
2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375: 1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
3. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA, Szilagyi PG, Griffin MR, Williams JV, Zhu Y, Grijalva CG, Prill MM, Iwane MK. 2013. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 132:e341- e348. http://dx.doi.org/10.1542/peds.2013-0303.
4. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162: 80-99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
5. Graham BS. 2011. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol. Rev. 239: 149-166. http://dx.doi.org/10.1111/j.1600-065X.2010.00972.x.
6. Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JF, Buick R, Stevenson NJ, Touzelet O, Gadina M, Power UF, Johnston JA. 2007. Respiratory syncytial virus NS1 protein degrades STAT2 by using the elongin-cullin E3 ligase. J. Virol. 81:3428 -3436. http://dx.doi.org/ 10.1128/JVI.02303-06.
7. Goswami R, Majumdar T, Dhar J, Chattopadhyay S, Bandyopadhyay SK, Verbovetskaya V, Sen GC, Barik S. 2013. Viral degradasome hijacks mitochondria to suppress innate immunity. Cell Res. 23:1025-1042. http://dx.doi.org/10.1038/cr.2013.98.
8. Ling Z, Tran KC, Teng MN. 2009. Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J. Virol. 83:3734-3742. http:// dx.doi.org/10.1128/JVI.02434-08.
9. Lo MS, Brazas RM, Holtzman MJ. 2005. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J. Virol. 79:9315-9319. http://dx.doi.org/10.1128/JVI.79.14.9315-9319.2005.
10. Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC. 2006. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology 344:328 -339. http:// dx.doi.org/10.1016/j.virol.2005.09.009.
11. Spann KM, Tran KC, Chi B, Rabin RL, Collins PL. 2004. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J. Virol. 78:4363- 4369. http://dx.doi.org/10.1128/ JVI.78.8.4363-4369.2004.
12. Spann KM, Tran KC, Collins PL. 2005. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J. Virol. 79: 5353-5362. http://dx.doi.org/10.1128/JVI.79.9.5353-5362.2005.
13. Swedan S, Musiyenko A, Barik S. 2009. Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J. Virol. 83:9682-9693. http://dx.doi.org/10.1128/ JVI.00715-09.
14. Hastie ML, Headlam MJ, Patel NB, Bukreyev AA, Buchholz UJ, Dave KA, Norris EL, Wright CL, Spann KM, Collins PL, Gorman JJ. 2012. The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways. Mol. Cell. Proteomics 11:108-127. http://dx.doi.org/10.1074/mcp.M111.015909.
15. Kotelkin A, Belyakov IM, Yang L, Berzofsky JA, Collins PL, Bukreyev A. 2006. The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response. J. Virol. 80:5958 -5967. http://dx.doi.org/10.1128/ JVI.00181-06.
16. Munir S, Hillyer P, Le Nouen C, Buchholz UJ, Rabin RL, Collins PL, Bukreyev A. 2011. Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathog. 7:e1001336. http://dx.doi.org/10.1371/journal.ppat.1001336.
17. Munir S, Le Nouen C, Luongo C, Buchholz UJ, Collins PL, Bukreyev A. 2008. Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J. Virol. 82:8780-8796. http:// dx.doi.org/10.1128/JVI.00630-08.
18. Bitko V, Shulyayeva O, Mazumder B, Musiyenko A, Ramaswamy M, Look DC, Barik S. 2007. Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-kappaB-dependent, interferon-independent mechanism and facilitate virus growth. J. Virol. 81:1786-1795. http://dx.doi.org/10.1128/JVI.01420-06.
19. Jin H, Cheng X, Traina-Dorge VL, Park HJ, Zhou H, Soike K, Kemble G. 2003. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21:3647-3652. http://dx.doi.org/ 10.1016/S0264-410X(03)00426-2.
20. Jin H, Zhou H, Cheng X, Tang R, Munoz M, Nguyen N. 2000. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 273: 210-218. http://dx.doi.org/10.1006/viro.2000.0393.
21. Teng MN, Whitehead SS, Bermingham A, St. Claire M, Elkins WR, Murphy BR, Collins PL. 2000. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J. Virol. 74:9317-9321. http://dx.doi.org/ 10.1128/JVI.74.19.9317-9321.2000.
22. Whitehead SS, Bukreyev A, Teng MN, Firestone CY, St Claire M, Elkins WR, Collins PL, Murphy BR. 1999. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol. 73:3438-3442.
23. Luongo C, Winter CC, Collins PL, Buchholz UJ. 2013. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, liveattenuated vaccine candidate that is phenotypically stable at physiological temperature. J. Virol. 87:1985-1996. http://dx.doi.org/10.1128/JVI.02769 -12.
24. Teng MN. 2012. The non-structural proteins of RSV: targeting interferon antagonists for vaccine development. Infect. Disord. Drug Targets 12: 129-137. http://dx.doi.org/10.2174/187152612800100170.
25. Lin YH, Deatly AM, Chen W, Miller LZ, Lerch R, Sidhu MS, Udem SA, Randolph VB. 2006. Genetic stability determinants of temperature sensitive, live attenuated respiratory syncytial virus vaccine candidates. Virus Res. 115:9-15. http://dx.doi.org/10.1016/j.virusres.2005.06.013.
26. Malkin E, Yogev R, Abughali N, Sliman J, Wang CK, Zuo F, Yang CF, Eickhoff M, Esser MT, Tang RS, Dubovsky F. 2013. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5-24 months of age. PLoS One 8:e77104. http://dx.doi.org/ 10.1371/journal.pone.0077104.
27. Crowe JE, Jr, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR. 1995. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 13:847- 855. http:// dx.doi.org/10.1016/0264-410X(94)00074-W.
28. Mueller S, Papamichail D, Coleman JR, Skiena S, Wimmer E. 2006. Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity. J. Virol. 80:9687-9696. http://dx.doi.org/10.1128/ JVI.00738-06.
29. Burns CC, Shaw J, Campagnoli R, Jorba J, Vincent A, Quay J, Kew O. 2006. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J. Virol. 80: 3259-3272. http://dx.doi.org/10.1128/JVI.80.7.3259-3272.2006.
30. Coleman JR, Papamichail D, Skiena S, Futcher B, Wimmer E, Mueller S. 2008. Virus attenuation by genome-scale changes in codon pair bias. Science 320:1784-1787. http://dx.doi.org/10.1126/science.1155761.
31. Nakamura Y, Gojobori T, Ikemura T. 2000. Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res. 28:292. http://dx.doi.org/10.1093/nar/28.1.292.
32. Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN, Plemper RK, Crowe JE, Jr, Moore ML. 2012. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434:129-136. http://dx.doi.org/10.1016/j.virol.2012.09.022.
33. Wright PF, Ikizler MR, Gonzales RA, Carroll KN, Johnson JE, Werkhaven JA. 2005. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J. Virol. 79:8651-8654. http://dx.doi.org/10.1128/JVI.79.13.8651-8654.2005.
34. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. 2002. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. 76:5654 -5666. http://dx.doi.org/10.1128/JVI.76.11.5654 -5666.2002.
35. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniewska K, Pretto C, Williams JV, Hotard A, Sherrill TP, Peebles RS, Jr, Moore ML. 2011. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J. Virol. 85: 5782-5793. http://dx.doi.org/10.1128/JVI.01693-10.
36. Heinze B, Frey S, Mordstein M, Schmitt-Gräff A, Ehl S, Buchholz UJ, Collins PL, Staeheli P, Krempl CD. 2011. Both nonstructural proteins NS1 and NS2 of pneumonia virus of mice are inhibitors of the interferon type I and type III responses in vivo. J. Virol. 85:4071- 4084. http:// dx.doi.org/10.1128/JVI.01365-10.
37. Bossert B, Marozin S, Conzelmann KK. 2003. Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3. J. Virol. 77:8661-8668. http://dx.doi.org/ 10.1128/JVI.77.16.8661-8668.2003.
38. Valarcher JF, Furze J, Wyld S, Cook R, Conzelmann KK, Taylor G. 2003. Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J. Virol. 77:8426-8439. http://dx.doi.org/10.1128/JVI.77.15.8426 -8439.2003.
39. Schlender J, Bossert B, Buchholz U, Conzelmann KK. 2000. Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize alpha/beta interferon-induced antiviral response. J. Virol. 74:8234-8242. http://dx.doi.org/10.1128/JVI.74.18.8234-8242.2000.
40. Swedan S, Andrews J, Majumdar T, Musiyenko A, Barik S. 2011. Multiple functional domains and complexes of the two nonstructural proteins of human respiratory syncytial virus contribute to interferon suppression and cellular location. J. Virol. 85:10090 -10100. http:// dx.doi.org/10.1128/JVI.00413-11.
41. Teng MN, Collins PL. 1999. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J. Virol. 73:466-473.
42. Vitiello M, Galdiero M, Finamore E, Galdiero S, Galdiero M. 2012. NF-kappaB as a potential therapeutic target in microbial diseases. Mol. Biosyst. 8:1108-1120. http://dx.doi.org/10.1039/c2mb05335g.
43. Mueller S, Coleman JR, Papamichail D, Ward CB, Nimnual A, Futcher B, Skiena S, Wimmer E. 2010. Live attenuated influenza virus vaccines by computer-aided rational design. Nat. Biotechnol. 28:723-726. http:// dx.doi.org/10.1038/nbt.1636.
44. Yang C, Skiena S, Futcher B, Mueller S, Wimmer E. 2013. Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice. Proc. Natl. Acad. Sci. U. S. A. 110:9481-9486. http://dx.doi.org/10.1073/pnas.1307473110.
45. Hershberg R, Petrov DA. 2008. Selection on codon bias. Annu. Rev. Genet. 42: 287-299. http://dx.doi.org/10.1146/annurev.genet.42.110807.091442.
46. Ikemura T. 1985. Codon usage and tRNA content in unicellular and multicellular organisms. Mol. Biol. Evol. 2:13-34.
47. Najafabadi HS, Goodarzi H, Salavati R. 2009. Universal functionspecificity of codon usage. Nucleic Acids Res. 37:7014 -7023. http:// dx.doi.org/10.1093/nar/gkp792.
48. Tuller T, Carmi A, Vestsigian K, Navon S, Dorfan Y, Zaborske J, Pan T, Dahan O, Furman I, Pilpel Y. 2010. An evolutionarily conserved mechanism for controlling the efficiency of protein translation. Cell 141: 344-354. http://dx.doi.org/10.1016/j.cell.2010.03.031.
49. Qian W, Yang JR, Pearson NM, Maclean C, Zhang J. 2012. Balanced codon usage optimizes eukaryotic translational efficiency. PLoS Genet. 8:e1002603. http://dx.doi.org/10.1371/journal.pgen.1002603.
50. Zhou M, Guo J, Cha J, Chae M, Chen S, Barral JM, Sachs MS, Liu Y. 2013. Non-optimal codon usage affects expression, structure and function of clock protein FRQ. Nature 495:111-115. http://dx.doi.org/10.1038/ nature11833.
51. Pechmann S, Frydman J. 2013. Evolutionary conservation of codon optimality reveals hidden signatures of cotranslational folding. Nat. Struct. Mol. Biol. 20:237-243. http://dx.doi.org/10.1038/nsmb.2466.